Amgen Posts 77% Response In Thyroid Eye Disease Study
Business

Amgen Posts 77% Response In Thyroid Eye Disease Study

April 6, 2026
Benzinga
Scroll

Amgen shares fall despite Phase 3 TEPEZZA OBI data showing 77 response rate and proptosis reduction in thyroid eye disease patients. Importance Rank: 1 read more

Amgen Posts 77% Response In Thyroid Eye Disease Study
Read Full Article
Benzinga
Benzinga

Coverage and analysis from United States of America. All insights are generated by our AI narrative analysis engine.

United States of America
Bias: center
You might also like

Explore More